Can you provide a comprehensive overview of all types of arthritis, including their presentations, symptoms, diagnostic tests, treatments, and emerging therapies?

Comprehensive Overview of Arthritis: Types, Presentations, Diagnosis, and Treatment

Major Types of Arthritis

Arthritis encompasses over 100 distinct conditions, but the most clinically significant forms are osteoarthritis (OA), rheumatoid arthritis (RA), psoriatic arthritis (PsA), and spondyloarthropathies. Each has distinct pathophysiology, presentation patterns, and treatment algorithms.

---

Osteoarthritis (OA)

Pathophysiology

OA is a whole-joint degenerative disorder driven by cartilage degradation, subchondral bone remodeling, synovial inflammation, biomechanical stress, and cellular senescence 1, 2. It affects 302 million people worldwide and is the leading cause of disability in older adults 3.

Clinical Presentation

• Pain: Worsens with activity, improves with rest
• Stiffness: Brief morning stiffness (<30 minutes), "gelling" after inactivity
• Joint involvement: Knees, hips, hands (especially first carpometacarpal joint), spine
• Physical findings: Bony enlargement, crepitus, limited range of motion, joint line tenderness
• No systemic symptoms: Absence of fever, weight loss, or prolonged morning stiffness distinguishes OA from inflammatory arthritis

Diagnostic Approach

• Clinical diagnosis is primary: characteristic pain pattern + age >50 + brief morning stiffness
• Imaging: Plain radiographs show joint space narrowing, osteophytes, subchondral sclerosis, cysts
• Laboratory tests: Normal inflammatory markers (ESR, CRP); used mainly to exclude inflammatory arthritis
• Synovial fluid: Non-inflammatory (<2000 WBC/μL) if aspiration performed

Treatment Algorithm

Core treatments (ALL patients) 4:

1. Exercise: Local muscle strengthening + general aerobic fitness (STRONG recommendation)
2. Weight loss: If BMI ≥25 for knee/hip OA (STRONG recommendation)
3. Patient education: Counter misconceptions that OA is inevitably progressive

Pharmacological stepwise approach 4, 3:

Step 1 - First-line:

• Topical NSAIDs for knee OA (STRONG recommendation)
• Paracetamol/acetaminophen: Regular dosing for pain relief
• Hand orthoses for first CMC joint OA (STRONG recommendation)

Step 2 - If inadequate response:

• Oral NSAIDs or COX-2 inhibitors: Lowest effective dose, shortest duration, ALWAYS with proton pump inhibitor 4
• Evaluate GI, renal, cardiovascular risks before prescribing
• Intraarticular glucocorticoid injections for knee OA (STRONG recommendation)

Step 3 - Additional options:

• Duloxetine (conditional recommendation for knee OA)
• Tramadol (conditional recommendation)
• Topical capsaicin for knee OA (conditional recommendation)

Adjunct non-pharmacological 4, 3:

• Tai chi (STRONG recommendation)
• Cane use (STRONG recommendation)
• Tibiofemoral bracing for tibiofemoral knee OA (STRONG recommendation)
• Acupuncture, thermal modalities (conditional recommendations)

NOT recommended 4:

• Glucosamine and chondroitin products
• Electroacupuncture

Emerging Therapies

Recent research highlights chondrocyte ferroptosis inhibition, neurovascular remodeling modulation, regenerative biologics, and AI-guided precision medicine as promising disease-modifying approaches 1, 2.

---

Rheumatoid Arthritis (RA)

Pathophysiology

RA is a chronic autoimmune disease with synovial inflammation, cartilage degradation, and bone erosion driven by dysregulated T cells, B cells, and proinflammatory cytokines (TNF-α, IL-6) 5, 6. Affects 1% of the population; lifetime risk 3.6% in women, 1.7% in men.

Clinical Presentation

• Symmetric polyarthritis: Hands (MCPs, PIPs), wrists, feet (MTPs) most common
• Morning stiffness: ≥1 hour duration
• Joint swelling: Soft tissue swelling (synovitis), NOT just bony enlargement
• Positive "squeeze test": Pain with compression of MCPs or MTPs 7
• Extra-articular manifestations: Rheumatoid nodules, interstitial lung disease, vasculitis, inflammatory eye disease (markers of severe disease) 5

Diagnostic Approach

Clinical examination is primary for detecting synovitis 7, 8. In doubtful cases, ultrasound, power Doppler, or MRI confirm synovitis 7, 8.

Essential laboratory tests 7:

• Complete blood count
• ESR and CRP (acute phase reactants)
• Rheumatoid factor (RF)
• Anti-CCP antibodies (more specific than RF)
• Urinalysis
• Transaminases
• Antinuclear antibodies (to exclude other diseases)

Prognostic factors for persistent/erosive disease 7:

• Number of swollen/tender joints
• Elevated ESR or CRP
• RF and anti-CCP positivity (especially high levels)
• Radiographic erosions on hand/foot X-rays

Treatment Algorithm

CRITICAL TIMING: Refer to rheumatologist within 6 weeks of symptom onset 7, 8. Early treatment (ideally within 3 months) prevents joint damage and improves outcomes 8.

Treatment goal: Achieve clinical remission (ACR-EULAR criteria) 8, 9.

Phase I - DMARD-naive patients 8, 9:

1. Methotrexate is the anchor drug (FIRST-LINE) 7, 8

   • Start in ALL patients at risk of persistent disease
   • Even if classification criteria not yet met

2. Adjunctive therapies:

   • Systemic glucocorticoids: Temporary (<6 months), lowest dose necessary 8
   • Intra-articular glucocorticoid injections: For local symptom relief 8
   • NSAIDs: After evaluating GI, renal, cardiovascular risks 7, 8

3. Monitoring: Assess disease activity every 1-3 months until remission achieved 7, 8

   • Tender/swollen joint counts
   • Patient/physician global assessments
   • ESR, CRP
   • Use composite measures (DAS28, CDAI, SDAI)

Phase II - Inadequate response to csDMARDs 9:

Add biological DMARD (bDMARD):

• TNF inhibitors (adalimumab, etanercept, infliximab, certolizumab, golimumab)
• IL-6 receptor inhibitors (tocilizumab, sarilumab)
• T-cell costimulation inhibitor (abatacept)
• Anti-CD20 (rituximab)

Phase III - Inadequate response to first bDMARD 9:

• Switch to another bDMARD (including within-class switch)
• OR JAK inhibitor (tsDMARD): Baricitinib, tofacitinib, upadacitinib

Non-pharmacological interventions 8:

• Dynamic exercises, occupational therapy, hydrotherapy
• Patient education programs
• Smoking cessation, dental care, weight control, vaccination assessment 8

Emerging Therapies

BTK inhibitors, novel JAK inhibitors, TLR4 inhibitors, nanotechnology-based drug delivery systems, biomimetic carriers targeting neutrophil extracellular traps (NETs), and precision medicine approaches are under investigation 10, 6, 11.

---

Psoriatic Arthritis (PsA)

Clinical Presentation

• Peripheral arthritis: Asymmetric oligoarthritis or symmetric polyarthritis
• Dactylitis ("sausage digits")
• Enthesitis: Achilles tendon, plantar fascia insertion points
• Axial involvement: Sacroiliitis, spondylitis
• Nail changes: Pitting, onycholysis
• Skin psoriasis: May precede, coincide with, or follow joint symptoms

Diagnostic Approach

• Clinical diagnosis based on inflammatory arthritis + psoriasis
• Imaging: X-rays show "pencil-in-cup" deformities, periostitis, ankylosis
• RF and anti-CCP typically negative
• Elevated ESR/CRP in active disease

Treatment Algorithm 12

Goal: Maximize health-related quality of life through symptom control, preventing structural damage, normalizing function 12.

Step 1 - Polyarthritis:

• csDMARD rapidly initiated: Methotrexate preferred if significant skin involvement 12

Step 2 - Monoarthritis/oligoarthritis with poor prognostic factors:

• Consider csDMARD if structural damage, high ESR/CRP, dactylitis, or nail involvement 12

Step 3 - Inadequate response to ≥1 csDMARD:

• Start bDMARD: IL-17 inhibitor or IL-12/23 inhibitor preferred if significant skin involvement 12
• TNF inhibitors also effective

Step 4 - Inadequate response to ≥1 csDMARD and ≥1 bDMARD:

• JAK inhibitor may be considered 12

Step 5 - Mild disease, inadequate csDMARD response, bDMARD/JAK inhibitor not appropriate:

• PDE4 inhibitor (apremilast) may be considered 12

Enthesitis management:

• NSAIDs or local glucocorticoid injections first
• If insufficient: bDMARD 12

Axial disease management:

• NSAIDs first-line
• If insufficient: TNF inhibitor (current practice); IL-17 inhibitor if significant skin involvement 12

Adjunctive therapies:

• NSAIDs for symptom relief 12
• Systemic glucocorticoids: Use cautiously at lowest effective dose 12
• Local glucocorticoid injections 12

---

Spondyloarthropathies (Including Ankylosing Spondylitis)

Clinical Presentation

• Inflammatory back pain: Insidious onset, age <40, improves with exercise, worsens with rest, nocturnal pain
• Sacroiliitis: Buttock pain, alternating sides
• Peripheral arthritis: Asymmetric, lower limb predominance
• Enthesitis: Achilles, plantar fascia
• Extra-articular: Uveitis, inflammatory bowel disease, psoriasis
• HLA-B27: Positive in 25-75% with UC and AS 13

Diagnostic Approach

• Clinical criteria + imaging
• MRI: Detects early sacroiliitis before X-ray changes
• X-rays: Sacroiliac joint fusion, "bamboo spine" in advanced disease
• HLA-B27 testing supportive but not diagnostic

Treatment

• NSAIDs: First-line for axial symptoms
• Intensive physiotherapy: Essential component 13
• TNF inhibitors: For inadequate response to NSAIDs 13
• IL-17 inhibitors: Effective alternative
• Sulfasalazine, methotrexate, azathioprine: Generally ineffective for axial disease 13

---

Arthritis Associated with Inflammatory Bowel Disease

Peripheral Arthropathy 13

Type I (4-17% of UC patients):

• Pauciarticular (<5 joints)
• Large weight-bearing joints (knees, ankles, hips, wrists)
• Acute, self-limiting (weeks)
• Activity mirrors UC activity
• Treatment: Treat underlying UC (corticosteroids, immunomodulators, anti-TNF agents)

Type II (2.5% of UC patients):

• Polyarticular
• Small joints of hands
• Independent of UC activity
• Treatment: Sulfasalazine effective; NSAIDs short-term with caution 13

Axial Arthropathy 13

• Sacroiliitis and spondylitis
• Independent of UC activity
• Treatment: Intensive physiotherapy + NSAIDs; anti-TNF therapy for refractory cases

---

Key Diagnostic Pitfalls and How to Avoid Them

1. Mistaking OA for inflammatory arthritis: OA has brief morning stiffness (<30 minutes), no systemic symptoms, normal inflammatory markers
2. Delaying RA referral: Any polyarticular joint swelling with pain/stiffness requires rheumatology referral within 6 weeks 7, 8
3. Missing early inflammatory arthritis: Use ultrasound/MRI when clinical examination equivocal 7, 8
4. Overlooking extra-articular manifestations: Uveitis, psoriasis, IBD symptoms, nodules indicate specific arthritis subtypes
5. Assuming negative RF/anti-CCP excludes RA: Seronegative RA exists; clinical presentation and imaging guide diagnosis
6. Using NSAIDs long-term without GI protection: Always prescribe PPI with oral NSAIDs/COX-2 inhibitors 4

---

Critical Treatment Principles Across All Arthritis Types

1. Early aggressive treatment prevents irreversible damage - particularly crucial in RA and PsA
2. Treat-to-target strategy: Monitor disease activity regularly (every 1-3 months) and escalate therapy until remission/low disease activity achieved 8, 9
3. Shared decision-making: Treatment decisions must involve patient preferences, comorbidities, and risk tolerance 8, 9
4. Multidisciplinary care: Rheumatologists lead, but physical therapy, occupational therapy, and patient education are essential 8
5. Address comorbidities: Cardiovascular disease, osteoporosis, infections, malignancy risk increase with inflammatory arthritis and treatments 8, 9